Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herceptin sBLA Submitted For Early-Stage Use

This article was originally published in The Pink Sheet Daily

Executive Summary

A supplemental BLA for an early adjuvant breast cancer indication for Herceptin will have a mid-August user fee date, if granted priority review

You may also be interested in...



Herceptin early-stage breast cancer user fee date extended

New deadline is November after Genentech provides FDA with additional analyses of previously submitted studies.

Herceptin early-stage breast cancer user fee date extended

New deadline is November after Genentech provides FDA with additional analyses of previously submitted studies.

Herceptin Less-Frequent Dosing Is Preferred For Early-Stage Breast Cancer, NICE Says

U.K.’s NICE supports adoption of three-week interval dosing for trastuzumab for early-stage HER2-positive breast cancer.

Related Content

Topics

UsernamePublicRestriction

Register

PS063693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel